Calithera Biosciences Inc. (CALA)

Overview

Calithera Biosciences, Inc. underwent a significant transition in January 2023, when it was resolved to operate under a plan of liquidation. Prior to this decision, the company had built its reputation on being a pioneer in the precision oncology biopharmaceutical domain, focusing on the clinical stage development of novel treatments. The entity, founded in the year 2010, had its foundations and operational headquarters in South San Francisco, California, marking itself as a notable player in the biotech industry. Calithera Biosciences Inc.'s journey from its inception to its decision to liquidate reflects a complex pathway filled with scientific endeavors aimed at revolutionizing cancer treatment through precision oncology.

Products and Services

No specific products and services description available due to the company's current operational status under a liquidation plan as of January 2023. Prior to this phase, Calithera Biosciences, Inc. was engaged in the development of innovative oncology products focusing on cancer's metabolic and immune checkpoints. Their work primarily included:

• Clinical Stage Oncology Drugs: Targeted therapies designed to exploit the unique metabolic requirements of tumor cells and the tumor microenvironment, aiming to improve patient outcomes in various cancer types.
• Precision Oncology Research: Research services aiming at identifying and validating novel therapeutic targets within the cancer metabolism and immune response pathways.